GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BeiGene Ltd (SHSE:688235) » Definitions » Investments And Advances

BeiGene (SHSE:688235) Investments And Advances : ¥878 Mil (As of Mar. 2025)


View and export this data going back to 2021. Start your Free Trial

What is BeiGene Investments And Advances?

BeiGene's Investments And Advances for the quarter that ended in Mar. 2025 was ¥878 Mil.

BeiGene's quarterly Investments And Advances declined from Sep. 2024 (¥978 Mil) to Dec. 2024 (¥939 Mil) and declined from Dec. 2024 (¥939 Mil) to Mar. 2025 (¥878 Mil).

BeiGene's annual Investments And Advances increased from Dec. 2022 (¥640 Mil) to Dec. 2023 (¥640 Mil) and increased from Dec. 2023 (¥640 Mil) to Dec. 2024 (¥939 Mil).


BeiGene Investments And Advances Historical Data

The historical data trend for BeiGene's Investments And Advances can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BeiGene Investments And Advances Chart

BeiGene Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Investments And Advances
Get a 7-Day Free Trial Premium Member Only Premium Member Only 322.68 641.97 639.86 640.08 938.72

BeiGene Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Investments And Advances Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,034.24 1,014.00 978.14 938.72 878.21

BeiGene Investments And Advances Calculation

Investments And Advances includes all the non-current investments in affiliates, real estate, securities, etc.


BeiGene Business Description

Address
c/o Mourant Governance Services (Cayman) Limited, 94 Solaris Avenue, Camana Bay, Grand Cayman, CYM, KY1-1108
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeiGene's revenue.

BeiGene Headlines

No Headlines